• Find an Expert
  • Contact
  • SearchSearch icon
  • Menu
  • Help
  • Report an issue

Contact


Email

weiguang@unimelb.edu.au

Credentials


Position
Senior Research Officer NH&MRC
Department of Microbiology and Immunology
Education
Bachelors Degree (Honours)
Jiangxi Medical College
Masters (Research)
National Institutes for Food and Drug Control
PhD
Eberhard-Karls-Universitaet Tuebingen
ORCID

0000-0002-0111-614X

Dr Weiguang Zeng

Senior Research Officer NH&MRC
Department of Microbiology and Immunology

140 Scholarly works
8 Projects

HIGHLIGHTS

  • 2025

    Journal article

    An integrated multi-omic approach for discovery and dereplication of bioactive microbial natural products
    DOI: 10.1099/mgen.0.001552
  • 2024

    Journal article

    Inclusion of TAT and NLS sequences in lipopeptide molecules generates homogenous nanoparticles for gene delivery applications
    DOI: 10.1016/j.ijpharm.2024.124492
  • 2023

    Journal article

    Development of Matrix-Embedded Bovine Tracheal Organoids to Study the Innate Immune Response against Bovine Respiratory Disease
    DOI: 10.3390/organoids2020007
  • 2022

    Journal article

    Abstract 3502: AXA-042 - a novel systemic TLR2/6 agonist for anti-tumor therapy
    DOI: 10.1158/1538-7445.am2022-3502
  • 2022

    Conference Proceedings

    AXA-042-a novel systemic TLR2/6 agonist for anti-tumor therapy
  • 2021

    Journal article

    TLR2-mediated activation of innate responses in the upper airways confers antiviral protection of the lungs
    DOI: 10.1172/jci.insight.140267
  • 2017

    Research Contracts

    SCHEDULE 7: INNA-006 Patent Exemplification
Weiguang Zeng

Latest Honours,
Awards and Fellowships


2021
University of Melbourne

RECENT SCHOLARLY WORKS

  • 2021

    Journal article

    Prophylactic intranasal administration of a TLR2/6 agonist reduces upper respiratory tract viral shedding in a SARS-CoV-2 challenge ferret model
    DOI: 10.1016/j.ebiom.2020.103153
  • 2020

    Journal article

    Vaccine-specific immune responses against mycobacterium ulcerans infection in a low-dose murine challenge model
    DOI: 10.1128/IAI.00753-19
  • 2020

    Journal article

    Modular platforms for the assembly of self-adjuvanting lipopeptide-based vaccines for use in an out-bred population
    DOI: 10.1016/j.vaccine.2019.10.055
  • 2019

    Journal article

    Geometry of a TLR2-Agonist-Based Adjuvant Can Affect the Resulting Antigen-Specific Immune Response
    DOI: 10.1021/acs.molpharmaceut.9b00026

RECENT PROJECTS

  • 2015

    Research contracts (non-grants)

    Lead Selection for Respiratory Program
  • 2013

    Research Contracts

    Utilization of TLR2 Agonist Pam2Cys as Adjuvant to Facilitate the Development of Staphylococcus Aureus and Respiratory Syncytial Virus Subunit Vaccines
  • 2013

    Internal Research Grant

    A New Vaccine to Prevent Diarrhoea Caused by Enterotoxigenic E. Coli (Etec)
  • 2009

    Research Grant

    Is Pam2Cys the New Anti-Viral Against Influenza a Virus?

We acknowledge and pay respect to the Traditional Owners of the lands upon which our campuses are situated

Read about our commitment to reconciliation  

About us  

Careers at Melbourne  

Safety and respect  

Newsroom  

Contact  

Phone: 13 MELB ( 13 6352)

International: +61 3 9035 5511


Address:
The University of Melbourne
Grattan Street, Parkville,
Victoria, 3010, Australia


View all Campus locations  
facebookIconlinkedinIconinstagramIcontwitterIcon

Emergency information  |  Disclaimer and copyright  |  Accessibility  |  Privacy  |  VaxFACTS

CRICOS number: 00116K     ABN: 84 002 705 224